IL-17 modulator 4 - An Overview
Other clinical trials in patients with non-Hodgkin's lymphoma [24] and individuals with Superior malignancy [14] have demonstrated also that zosuquidar did not substantially influence the pharmacokinetics of doxorubicin and had moderate consequences about the pharmacokinetics of vincristine. These medical trials accepted that zosuquidar could secur